Solid Biosciences Inc.
NASDAQ:SLDBBiotechnology
+$0.27 today
- Market cap
- $695.33M
- Beta
- 2.43
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$1.75
Volume 1.13M
Average 1.39M
SLDB Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Solid Biosciences Inc.NASDAQ: SLDB
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $56.74M (cash outflow) rose 44.4% year over year, ahead of the +37.3% change in trailing-twelve-month net income. Sequentially, it rose 14.0% from the prior quarter. Over 3 fiscal years it compounded at +26.6% a year.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 10 analysts of -$144.16M (-17.3%) for the fiscal year ending Dec 2026, a slowdown from the +39.8% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$56.74M+14.0% QoQ
- Last fiscal yearDec 2025
- -$174.33M+39.8% YoY
- LTMMar 2026
- -$191.78M+37.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +44.4% | +68.3% | +23.8 pp |
| 1 year | +39.8% | -17.3% | -57.1 pp |
| 3-year CAGR | +26.6% | -26.5% | -53.1 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (174.33M) USD
- Year-over-year change
- -39.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (174.33M) | -39.8% |
| FY2024 | 2024-12-31 | (124.7M) | -29.9% |
| FY2023 | 2023-12-31 | (96.02M) | -11.7% |
| FY2022 | 2022-12-31 | (85.98M) | -19.1% |
| FY2021 | 2021-12-31 | (72.19M) | — |
Net Income vs competitors
How SLDB compares with its peers on the latest reported figures
- SLDB's LTM Mar 2026 net income of $191.78M is the 5th largest of the 10 companies compared; the peer median is $98.64M.
- Its year-over-year change of +37.3% is the 5th highest of 10, against a peer median of +25.8%.
- Over three fiscal years its annual growth of +26.6% compares with a peer median of +13.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $80.71B | +146477.0% | +53.5% | — | |
| LTM Sep 2026 | $1.18B | +848.8% | +35.4% | — | |
| LTM Jun 2026 | $519.41M | +25.8% | +38.5% | — | |
| LTM Mar 2026 | $328.6M | +96.4% | -4.1% | 412.0% | |
| LTM Mar 2026 | $191.78M | +37.3% | +26.6% | — | |
| LTM Mar 2026 | $160.9M | -8.8% | +9.2% | 182.3% | |
| LTM Mar 2026 | $98.64M | +22.0% | +17.9% | — | |
| LTM Mar 2026 | $77.22M | -24.4% | +9.1% | — | |
| LTM Mar 2026 | $65.06M | +126.2% | +0.5% | 3.0% | |
| LTM Jun 2026 | $38.38M | -106.1% | — | 3.8% | |
| Peer median (excluding SLDB) | $98.64M | +25.8% | +13.5% | 93.1% | |
Competitors are the stored peer set for SLDB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (72.19M) | (85.98M) | (96.02M) | (124.7M) | (174.33M) |
| Depreciation & Amortization | 2.96M | 2.41M | 2.58M | 2.46M | (1.87M) |
| Deferred Income Tax | 1.21M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 13.37M | 7.54M | 7.63M | 10.52M | 16.91M |
| Change in Working Capital | (23.04M) | (3.69M) | (6.34M) | 2.85M | (6.82M) |
| Accounts Receivables | (110K) | 110K | 0 | 0 | 0 |
| Inventory | (11.5M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.21M | (5.25M) | (764K) | 2.21M | (1.09M) |
| Other Working Capital | (12.64M) | 1.45M | (5.57M) | 645K | (5.73M) |
| Other Non-Cash Items | (81K) | (18.25M) | (2.03M) | 8.86M | 9.82M |
| Operating Cash Flow | (77.76M) | (97.98M) | (94.18M) | (100.01M) | (156.29M) |
| Capital Expenditures | (1.28M) | (3.02M) | (1.52M) | (654K) | (1.15M) |
| Acquisitions (Net) | 89.81M | 31.52M | 0 | 5K | 85K |
| Purchases of Investments | (141.25M) | (182.76M) | (117.43M) | (204.34M) | (235.89M) |
| Sales of Investments | 51.44M | 212.81M | 128.63M | 188.9M | 178.5M |
| Other Investing Activities | (89.81M) | 600K | 0 | 0 | 0 |
| Investing Cash Flow | (91.09M) | 59.16M | 9.69M | (16.09M) | (58.45M) |
| Debt Repayment | 0 | 2.08M | 0 | (473K) | (723K) |
| Common Stock Issued | 134.88M | 72.55M | 2.97M | 127.23M | 194.74M |
| Common Stock Repurchased | 0 | 0 | 0 | (5.11M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 107K | 203K | 148K | 794K | 425K |
| Financing Cash Flow | 134.99M | 74.83M | 3.12M | 122.44M | 194.45M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (33.87M) | 36.01M | (81.37M) | 6.34M | (20.3M) |
| Free Cash Flow | (79.05M) | (100.99M) | (95.7M) | (100.67M) | (157.44M) |
Solid Biosciences Inc.
NASDAQ:SLDB
Intrinsic Alpha fair value
Locked
Current Price
$6.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.